Are you Dr. Dickler?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 82 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
205 E 64th St
New York, NY 10021Phone+1 212-639-2000Fax+1 212-794-5847- Is this information wrong?
Summary
- Dr. Maura Dickler, MD is an oncologist in New York, New York. She is currently licensed to practice medicine in New York and Illinois. She is affiliated with Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals / Bellevue.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
University of ChicagoResidency, Internal Medicine, 1991 - 1994
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1991
Certifications & Licensure
NY State Medical License 1995 - 2026
IL State Medical License 1991 - 1996- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- Top Doctors: New York Metro Area Castle Connolly, 2005-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Estrogen Receptor (ER)-Negative and Progesterone Receptor (PR)-Negative Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease Start of enrollment: 1999 Apr 01
- Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2002 Dec 01
- Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease Start of enrollment: 1999 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.Sarat Chandarlapaty, Maura N Dickler, Jose Alejandro Perez Fidalgo, Rafael Villanueva-Vázquez, Jennifer Giltnane, Mary Gates, Ching-Wei Chang, Sravanthi Cheeti, Jill F...> ;Clinical Cancer Research. 2023 Aug 1
- 7 citationsGenome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimensJulia C F Quintanilha, Jin Wang, Alexander B. Sibley, Wei Xu, Osvaldo Espin-Garcia, Chen Jiang, Amy S. Etheridge, Mark J. Ratain, Heinz-Josef Lenz, Monica M. Bertagnol...> ;International Journal of Cancer. 2022 Jan 15
- 4 citationsA clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapyMei Yin C. Polley, Maura N. Dickler, Jason P. Sinnwell, Kathleen S. Tenner, Juan de la Haba, Sibylle Loibl, Matthew P. Goetz, Jonas Bergh, John Roberston, Fergus J. Co...> ;Breast Cancer Research and Treatment. 2021 Jul 3
- Join now to see all
Authored Content
- A Phase IIA Trial of Acupuncture to Reduce Chemotherapy-Induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer PatientsAugust 2018
Press Mentions
NCCN Patient Advocacy Summit Emphasizes Treating Every Cancer Patient as an IndividualDecember 10th, 2020- Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly OncologyDecember 3rd, 2020
FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (Ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung CancerFebruary 27th, 2020- Join now to see all
Professional Memberships
- Member
- Member
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York
NYC Health + Hospitals / BellevueNew York, New York
